Fibrocell Science, Inc. announced the initiation of a Phase II trial for azficel-T, an autologous
fibroblast cellular product, for the treatment of restrictive burn scars (RBS). According to a release, the Phase II double-blind, randomized, placebo-controlled ...
[Published Individual.com - May 08 2013]